HighTower Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

HighTower Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,700	Closed	-$2K	–	2397
2018 Q1	$2K	Buy	+3,700	New	+$216K	﹤0.01%	2161
2017 Q4	–	Sell	-1,200	Closed	-$5K	–	2411
2017 Q3	$5K	Buy	1,200 +200	+20%	+$15.9K	﹤0.01%	2171
2017 Q2	$11K	Buy	+1,000	New	+$61.2K	﹤0.01%	2111

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HighTower Advisors's CLVS Position: Q2 2019 in Review

HighTower Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 8,375 shares — an estimated $207K sold.

HighTower Advisors first reported a position in CLVS in Q2 2015 and held it in 11 quarters. The position peaked at $598K in Q3 2016. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

HighTower Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
HighTower Advisors sold 8,375 Clovis Oncology, Inc. shares in Q2 2019, an estimated $207K.
HighTower Advisors first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 11 quarters.
HighTower Advisors's Clovis Oncology, Inc. position peaked at $598K in Q3 2016.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on HighTower Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.